SQZ Biotechnologies Co - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SQZ New York 8731 https://sqzbiotech.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SQZ Biotechnologies Co

SQZ Biotechnologies Company (SQZ) Reports Q1 Loss, Misses Revenue Estimates - May 10th, 2023 11:15 pm
SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates - May 10th, 2023 8:45 pm
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates - May 8th, 2023 9:15 pm
Investors Aren't Entirely Convinced By SQZ Biotechnologies Company's (NYSE:SQZ) Revenues - Apr 17th, 2023 12:07 pm
SQZ Biotech's Cancer Candidate Shows Response At Low Dose In HPV16+ Solid Tumor Patient - Mar 23rd, 2023 3:28 pm
SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial - Mar 22nd, 2023 8:50 pm
SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates - Mar 22nd, 2023 8:45 pm
SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange - Jan 18th, 2023 9:30 pm
We're Keeping An Eye On SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Rate - Jan 18th, 2023 11:19 am
SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress - Dec 6th, 2022 11:45 am
Roche-partnered cell therapy company lays off most of its staff, loses CEO, CFO - Dec 1st, 2022 7:10 pm
SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer - Nov 30th, 2022 9:30 pm
SQZ Biotechnologies Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag - Nov 12th, 2022 12:56 pm
SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting - Nov 10th, 2022 2:00 pm
SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates - Nov 9th, 2022 9:30 pm
Multiple insiders bought SQZ Biotechnologies Company (NYSE:SQZ) stock earlier this year, a positive sign for shareholders - Nov 8th, 2022 2:07 pm
Analyst Bullish On SQZ Biotech's Technology For Solving Cell Therapy Challenges - Oct 20th, 2022 7:06 pm
SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived Immunotherapy - Oct 3rd, 2022 10:45 am
SQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies - Sep 12th, 2022 10:00 am
SQZ Biotechnologies to Present at Upcoming Investor Conferences - Sep 7th, 2022 8:30 pm